



PRESS RELEASE

10 August 2023, 07:00 CEST

## **Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla™ Platform**

**Mechelen, Belgium, 2023** - Biocartis Group NV (the 'Company' or 'Biocartis'), a global innovative molecular diagnostics company (Euronext Brussels: BCART) today announced that they have entered into a new post-commercial collaboration program with Lilly, a global pharmaceutical company. This program will explore the advantages of adding the Biocartis Idylla™ Platform to a molecular diagnostics workflow in global clinical labs via a study in hospitals across Spain. The focus will be to understand how the Idylla™ Platform can contribute to a more expeditious and comprehensive approach to identify targetable alterations when compared to various current clinical workflows for NSCLC patients.

**Roger Moody, Chief Executive Officer of Biocartis, commented:** *"I am pleased that Lilly shares our commitment to address the need for faster identification of eligible patients for targeted therapy."* He also added: *"Despite guidelines and reimbursement, patients, especially those in community hospital settings, continue to receive treatment based on incomplete or untimely biomarker results. Our collaboration with Lilly supports our ambition to deliver results in time for all patients, including those being treated in community-based centers."*

The intention of the Lilly-sponsored study in Spain is that the results will guide and improve US community-based diagnostic workflows by the introduction of the Idylla platform. The outcome data is expected to be presented in the fall of 2024.

**Anthony Sireci, MD, MSC, Senior Vice President, Clinical Biomarker and Diagnostics, Loxo Oncology at Lilly, added:** *"There is a need to improve the rates of molecular profiling of lung cancer patients before first line treatment decisions are made. One of the barriers to this are the long turnaround times associated with send out testing. This study aims to test the hypothesis that an in-house, rapid turnaround time and easy to use assay will deliver actionable results to patients and increase their likelihood of receiving biomarker-informed therapies."*

----- END -----

### **More information:**

Investor Relations Biocartis  
e-mail [ir@biocartis.com](mailto:ir@biocartis.com)

### **About Biocartis**

With its revolutionary and proprietary Idylla™ platform, Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla™'s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung and liver cancer, as well as for COVID-19 and sepsis. More information: [www.biocartis.com](http://www.biocartis.com). Follow us on [Twitter](https://twitter.com/Biocartis_): @Biocartis\_.

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.

*This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.*

**Forward-looking statements**

*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*